Evolus announces positive topline results in NLF study

Evolus announced positive topline results from a U.S. pivotal nasolabial fold or NLF, study of dermal filler products Evolysse Lift and Smooth. Data were presented at the 2024 SCALE Meeting on May 17, in Nashville. “Achieving positive topline results in our NLF study is a pivotal step supporting the upcoming submission of our Premarket Approval application for the U.S. launch of our dermal filler lines. Complementing our flagship neurotoxin Jeuveau, the fastest growing neurotoxin in the U.S. for the past three years1 – our Evolysse line of dermal fillers expands our total addressable market by 78%,” said David Moatazedi, President and Chief Executive Officer… The 6-month primary endpoint measured the change in NLF severity from baseline and was assessed by a blinded independent photographic review panel using a validated 5-point nasolabial scale.